This study is about trying new treatments for acute myeloid leukemia (AML), a type of blood cancer. It uses a special method called genomic screening to decide which treatment is best for each person based on their cancer type. Genomic screening looks at the genes (DNA) of the cancer cells to find the best plan. If a person's cancer doesn't fit any specific group, they can still join a part of the study for those without identified markers. The study is in phases, starting with Phase 1b and 2, which are early stages to see how well new treatments work and if they are safe.

• Participants should be 60+ years old, except in special cases where 18+ is allowed.
• Some people might not be able to join, like those with certain medical conditions.
• The study may involve different treatments based on genomic results and AML type.